Moreover, the use of BEVs expressing SLC7A11 siRNA presents a novel strategy for targeted gene silencing in lung cancer therapy, promoting ferroptosis as a mechanism to inhibit tumor progression. Here, SLC7A11 is linked to lung cancer.